Cell Line Development Market Size, Share, and Analysis by 2027

[Research Report] The cell line development market was valued at US$ 4,160.42 million in 2019 and is projected to reach US$ 11,219.87 million by 2027; it is expected to grow at a CAGR of 13.3% from 2020 to 2027.

Market Insights and Analyst View:

Cell line development is the process by which the cellular machinery is co-opted to manufacture therapeutic biologics or other proteins of interest. The cell line is an established cell culture where the cells multiply in the appropriate growth medium and space for growth. Cell lines allow gradual alterations in the structure, physiology, and genetic structure of cells under a customized environment. The increasing investments in research and development by pharmaceutical and biotechnology companies, coupled with the increasing adoption of regenerative medicines, are expected to propel the cell line development market growth during the forecast period.

Growth Drivers and Challenges:

In recent years, the cases of cancer have been increasing tremendously and the trend is anticipated to remain the same in the upcoming years. Changes in lifestyle has resulted in more exposure to oncogenic factors. Cancer is one of the leading cause of deaths globally and is profoundly affecting the quality of life. As per World Health Organization in 2020 stats, approximately 10 million deaths across the globe were due to cancer. For instance, as per American Cancer Society, in 2020, there will be an expected 1.8 million new cancer cases detected and 606,520 cancer deaths in the US. Cancer can be cured if diagnosed and treated at an initial stage. Cancer sequencing using next-generation sequencing (NGS) methods provides more information. Additionally, cell line development also aids in research, diagnostics and treatment of cancer.

The increasing involvement of several CDMOs in the cell line development market is propelling the market's growth rate. For instance, ABC Biologics was named the Leading Innovator in mammalian cell line development for the US in 2022, supporting cell line development market growth.

Published Report - Cell Line Development Market: Strategic Insights

Sino Biological is a contract research organization (CRO) specializing in the recombinant production of proteins and antibodies, with routine high throughput projects of up to 1,000 per batch. Similarly, Aragen Bioscience, Inc, a leading pre-clinical contract research organization, introduced RapTr services. RapTr Cell Line Development Services combine the proven CHO-DG44 host cell line and vector combination with an innovative clone selection process. Multiple numbers of cell line development CRO companies are offering cell line development services, thus propelling market growth.

Thus, above mentioned factors are expected to boost the cell line development market.

Report Segmentation and Scope:

The “Global Cell Line Development Market” is segmented based on type, product, application, and geography. Based on type, the cell line development market is segmented into primary cell line, hybridomas, continuous cell lines, and recombinant cell line. Based on product, the cell line development market is segmented into equipment, media and reagent. Based on application, the cell line development market is segmented into drug discovery, bioproduction, and tissue engineering. The cell line development market based on geography is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America)

Segmental Analysis:

Based on type, the cell line development market is segmented into primary cell line, hybridomas, continuous cell lines, and recombinant cell line. Recombinant cell line segment held the largest share of the market. Moreover, the hybridomas segment is expected to register the highest CAGR of 14.1% in the market during the forecast period. Recombinant cell lines are preferred systems for the production of therapeutic recombinant proteins. Recombinant mammalian cell lines have been most commonly used for production of recombinant proteins due to its similarity in metabolic and protein processing pathways to those in human cells. Biotherapeutic proteins have been used for treatment of various conditions like infectious diseases, autoimmune disorders, hormonal dysregulation, hematologic disorders, cancers, and genetic disorders. Thus, the growing adoption of recombinant cell line for the production of biotherapeutic recombinant proteins is likely to grow the demand of recombinant cell line during the forecast period.

Based on product, the cell line development market is segmented into equipment, media and reagent. In 2019, the media and reagent-based segment held the largest share of the market. Moreover, the same segment is also expected to register the highest CAGR of 13.8% in the market during the forecast period. A growth medium/culture medium is a liquid or gel which supports the growth of cells in invitro conditions. The media contains crucial components like a source of energy and compounds that regulate the cell cycle. As media and reagents are important part of the cell line development process, the market for media and reagent is likely to witness rapid growth during the forecast period.

Based on application, the cell line development market is segmented into drug discovery, bioproduction, and tissue engineering. In 2019, the bioproduction segment held the largest share of the market. However, the drug discovery segment is expected to register the highest CAGR of 14.3% in the market during the forecast period. Cell lines are the preferred expression systems for producing recombinant, large, complex proteins with post-translational modifications. Chinese hamster ovary (CHO) cell line is the most common mammalian cell line used for production of recombinant protein. Many of the market players are offering cell lines for bioproduction. For instance, Creative Biogene provides comprehensive services for generating bioproduction stable cell lines. Creative Biogene is experience at developing bioproduction cell lines that includes robust vector design and construction, gene synthesis, gene delivery with high efficiency, and rigorous Q&C system etc. Similarly, due to considerable genomic research and development activities, biotherapeutic cell line development has reached new frontiers. In addition, existing and emerging technologies in the biotherapeutics cell line development have played an integral role in pushing cell development market toward new frontiers.

Regional Analysis:

Based on geography, the cell line development market is divided into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. North America cell line development market has been analysed based on three major countries — the US, Canada, and Mexico. The US is estimated to hold the largest cell line development market share during the forecast period. The cell line development market growth in the US is attributed to the various market players, and dynamic scenario has been established in this region have transformed the dynamics of cell line development in the region. The growth in North America is characterized by an increase in the demand for innovative products from biopharmaceutical and biotechnology companies, the presence of key market players, and extensive research and development conducted by various academic and research institutes. Moreover, increasing focus on advanced method incorporation in healthcare, government, and private initiatives for promotion of precision medicine and massive funds from government and private bodies for genomic research are further expected to stimulate growth and contribute to exceptional revenue generation for the cell line development market in North America. The medical biotechnology has undergone revolutions as a result of various development programs, business strategies that helps to produce, discover, or alter various biomolecules and organisms through bioengineering approaches. The Biotech Startup Revolution has also assisted in promoting the new ventures holding promising and innovative ideas in the country and supported in maximizing the revenue generation and thus the economic position of North America in the global cell line development market.

Furthermore, various launches of technologically advanced product for cell line development are expected to boost market growth. For instance, in October 2021, BICO company introduced CYTENA, a new platform for completely automated stable cell line development. The platform combines CYTENA's best-in-class liquid handling expertise for cost-effective and superior laboratory automation. The democratization of access to the production of next-generation healthcare solutions, such as antibody therapies, gene therapies, and biosimilar production, furthers BICO's Bio Convergence agenda.

Europe is the second leading region in the global cell development market. Germany is holding the largest share in the Europe cell line development market during the forecast period due to the factors such as government and private funding for biotechnology research, the launch of innovative technologies for cell line synthesis, and an increase in various research for novel technology-based applications are likely to be the significant factors driving the growth of this market in this region.

Industry Developments and Future Opportunities: 

Various initiatives taken by key players operating in the global cell line development market are listed below:

1. In July 2022, ProBioGen and Granite Bio collaborated to provide GMP manufacturing and Cell Line Development Services. A novel monoclonal antibody developed by Granite Bio is the company's top candidate for the treatment of autoimmune and specific cancer indications, by using the DirectedLuck transposase.
2. In June 2022, FUJIFILM Corporation invested US$ 1.6 billion to enhance and expand the cell culture manufacturing services of FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, and world-leading contract development and manufacturing organization (CDMO). This investment will also expand cell culture manufacturing solutions at the FUJIFILM Diosynth Biotechnologies’ Texas site. FUJIFILM Diosynth Biotechnologies will implement its proprietary SymphonX production equipment, enabling cGMP MaruX continuous processing at the single-use cell culture manufacturing site.
3. In April 2019, Lonza introduced CellBio Services, a comprehensive portfolio of unique, custom solutions designed to meet specific, individual research application needs.
4. In June 2019, Thermo Fisher Scientific launhced Cytomat 2 C-LiN Series automated incubator for cell cultures. This instrument has specifications such as automated controlled humidity, in-built contamination reduction system, and other advanced features.
5. In October 2019, Merck acquired FloDesign Sonics a US based company. FloDesign Sonics is a developer of distinctive acoustic cell processing platform that is applicable for the industrialization of cell and gene therapy manufacturing.

Cell Line Development

Published Report - Cell Line Development Market Players Density: Understanding Its Impact on Business Dynamics

The Published Report - Cell Line Development Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Covid-19 Impact: 

As per the study titled "Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening" published in the Journal Viruses in June 2022, Researchers have described the creation of a suitable human cell line for the high-throughput testing of antiviral medications that target the coronavirus 2 that causes severe acute respiratory syndrome (SARS-CoV-2). Angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), two essential host proteins required for viral entry, were engineered to express high levels in the human lung carcinoma cell line A549. Resulting, development of more cell lines to manage COVID-19, which had a significant impact on the cell line development market during the pandemic.

Competitive Landscape and Key Companies:

Some of the prominent players operating in the global cell line development market include Thermo Fisher Scientific Inc., Merck KGaA, Selexis SA (JSR Corporation), BioFactura, Inc., Corning Incorporated, Sartorius AG, Lonza, GENERAL ELECTRIC, LakePharma, Inc., and WuXi AppTec Group among others. These companies focus on new product launches and geographical expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which provides them to serve a large set of customers and subsequently increases their cell line development market share.